Clinical and magnetic resonance imaging predictors of disease progression in multiple sclerosis: A nine-year follow-up study

Multiple Sclerosis

Volumn 20, Issue 2, 2014, Pages 220-226

  Lavorgna, L ^a   Bonavita, S ^a,b   Ippolito, D ^a   Lanzillo, R ^c   Salemi, G ^d   Patti, F ^e   Valentino, P ^f   Coniglio, G ^g   Buccafusca, M ^h   Paolicelli, D ⁱ   D'Ambrosio, A ^a   Bresciamorra, V ^c   Savettieri, G ^d   Zappia, M ^e   Alfano, B ^j   Gallo, A ^a   Simone, I L ⁱ   Tedeschi, G ^a,b  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b Neurological Institute for Diagnosis and Care Hermitage Capodimonte   (Italy)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^d UNIVERSITY OF PALERMO   (Italy)

^e UNIVERSITY OF CATANIA   (Italy)

^f UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^g Department of Neurology   (Italy)

^h UNIVERSITY OF MESSINA   (Italy)

ⁱ UNIVERSITY OF BARI   (Italy)

^j CNR   (Italy)

more..

Author keywords

clinical predictors; follow up; gray matter atrophy; Magnetic resonance imaging; multiple sclerosis

Indexed keywords

ADULT; ARTICLE; BRAIN SIZE; CLINICAL ASSESSMENT; CROSS-SECTIONAL STUDY; DISEASE COURSE; EXPANDED DISABILITY STATUS SCALE; FEMALE; FOLLOW UP; GRAY MATTER; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PREDICTION;

CLINICAL PREDICTORS; FOLLOW-UP; GRAY MATTER ATROPHY; MAGNETIC RESONANCE IMAGING; MULTIPLE SCLEROSIS;

ADULT; CROSS-SECTIONAL STUDIES; DISABILITY EVALUATION; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING;

EID: 84893139638     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458513494958     Document Type: Article

References (35)

1. Lassmann H, Bruck W, Lucchinetti CF. The immunopathology of multiple sclerosis: An overview. Brain Pathol. 2007 ; 17: 210-218
2. Weinshenker BG. The natural history of multiple sclerosis. Neurol Clin. 1995 ; 13: 119-146
3. Confavreux C, Vukusic S. Natural history of multiple sclerosis: A unifying concept. Brain. 2006 ; 129: 606-616
4. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology. 1983 ; 33: 1444-1452
5. Confavreux C, Aimard G, Devic M. Course and prognosis of multiple sclerosis assessed by the computerized data processing of 349 patients. Brain. 1980 ; 103: 281-300
6. Runmarker B, Andersen O. Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-up. Brain. 1993 ; 116: 117-134
7. Confavreux C, Vukusic S, Adeleine P. Early clinical predictors and progression of irreversible disability in multiple sclerosis: An amnesic process. Brain. 2003 ; 126: 770-782
8. Pittock SJ, McClelland RL, Mayr WT, et al. Clinical implications of benign multiple sclerosis: A 20-year population-based follow-up study. Ann Neurol. 2004 ; 56: 303-306
9. Pittock SJ, Mayr WT, McClelland RL, et al. Change in MS-related disability in a population-based cohort: A 10-year follow-up study. Neurology. 2004 ; 62: 51-59
10. Weinshenker BG, Rice GP, Noseworthy JH, et al. The natural history of multiple sclerosis: A geographically based study. 3. Multivariate analysis of predictive factors and models of outcome. Brain. 1991 ; 114: 1045-1056
11. Renoux C. Natural history of multiple sclerosis: Long-term prognostic factors. Neurol Clin. 2011 ; 29: 293-308
12. Kappos L, Moeri D, Radue EW, et al. Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: A meta-analysis. Lancet. 1999 ; 353: 964-969
13. Fisniku L, Brex P, Altmann D, et al. Disability and T2 MRI lesions: A 20-year follow-up of patients with relapse onset of multiple sclerosis. Brain. 2008 ; 131: 808-817
14. Di Filippo M, Anderson VM, Altmann DR, et al. Brain atrophy and lesion load measures over 1 year relate to clinical status after 6 years in patients with clinically isolated syndromes. J Neurol Neurosurg Psychiatry. 2010 ; 81: 204-208
15. Sailer M, Losseff NA, Wang L, et al. T1 lesion load and cerebral atrophy as a marker for clinical progression in patients with multiple sclerosis. A prospective 18 months follow-up study. Eur J Neurol. 2001 ; 8: 37-42
16. Rudick RA, Lee JC, Simon J, et al. Significance of T2 lesions in multiple sclerosis: A 13-year longitudinal study. Ann Neurol. 2006 ; 60: 236-242
17. Tiberio M, Chard DT, Altman DP, et al. Gray and white matter volume changes in early RRMS. A 2-year longitudinal study. Neurology. 2005 ; 64: 1001-1007
18. Fisher E, Rudick RA, Simon JH, et al. Eight-year follow-up study of brain atrophy in patients with MS. Neurology. 2002 ; 59: 1412-1420
19. Fisniku L, Chard DT, Jackson JS, et al. Gray matter atrophy is related to long-term disability in multiple sclerosis. Ann Neurol. 2008 ; 64: 247-254
20. Tedeschi G, Lavorgna L, Russo P, et al. Brain atrophy and lesion load in a large population of patients with multiple sclerosis. Neurology. 2005 ; 65: 280-285
21. Horakova D, Dwyer MG, Havrdova E, et al. Gray matter atrophy and disability progression in patients with early relapsing-remitting multiple sclerosis: A 5-year longitudinal study. J Neurol Sci. 2009 ; 282: 112-119
22. Vaneckova M, Seidl Z, Krasensky J, et al. Patients' stratification and correlation of brain magnetic resonance imaging parameters with disability progression in multiple sclerosis. Eur Neurol. 2009 ; 6: 278-284
23. Alfano B, Brunetti A, Covelli EM, et al. Unsupervised, automated segmentation of the normal brain using a multispectral relaxometric magnetic resonance approach. Magn Reson Med. 1997 ; 37: 84-93
24. Alfano B, Brunetti A, Larobina M, et al. Automated segmentation and measurement of global white matter lesion volume in patients with multiple sclerosis. J Magn Reson Imaging. 2000 ; 12: 799-807
25. Freedman MS, Selchen D, Arnold DL, et al. Treatment optimization in MS: Canadian MS Working Group updated recommendations. Can J Neurol Sci. 2013 ; 40: 307-323
26. Li DK, Held U, Petkau J, et al. MRI T2 lesion burden in multiple sclerosis: A plateauing relationship with clinical disability. Neurology. 2006 ; 66: 1384-1389
27. Filippi M, Paty DW, Kappos L, et al. Correlations between changes in disability and T2-weighted brain MRI activity in multiple sclerosis: A follow-up study. Neurology. 2005 ; 45: 255-260
28. Truyen L, van Waesberghe JH, van Walderveen MA, et al. Accumulation of hypointense lesions ("black holes") on T1 spin-echo MRI correlates with disease progression in multiple sclerosis. Neurology. 1996 ; 47: 1469-1476
29. Koudriatseva T, Thompson AJ, Fiorelli M, et al. Gadolinium-enhanced MRI predicts clinical and MRI disease activity in relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry. 1997 ; 67: 285-287
30. Roosendaal SD, Bendfeldt K, Vrenken H, et al. Grey matter volume in a large cohort of MS patients: Relation to MRI parameters and disability. Mult Scler. 2011 ; 17: 1098-1106
31. Geurts JJ, Calabrese M, Fisher E, et al. Measurement and clinical effect of grey matter pathology in multiple sclerosis. Lancet Neurol. 2012 ; 11: 1082-1092
32. Mostert JP, Koch MW, Steen C, et al. T2 lesions and rate of progression of disability in multiple sclerosis. Eur J Neurol. 2010 ; 17: 1471-1475
33. Rudick RA, Lee JC, Cutter GR, et al. Disability progression in a clinical trial of relapsing-remitting multiple sclerosis: Eight-year follow-up. Arch Neurol. 2010 ; 67: 1329-1335
34. Noseworthy JH, Vandervoort MK, Wong CJ, et al. Interrater variability with the Expanded Disability Status Scale (EDSS) and functional systems (FS) in a multiple sclerosis clinical trial. Neurology. 1990 ; 40: 971-975
35. Goodkin DE, Cookfair D, Wende K, et al. Inter-intrarater scoring agreement using grades 1.0 to 3 5 of the Kurtzke Expanded Disability Status Scale (EDSS). Neurology. 1992 ; 42: 859-863